{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:52:12Z","timestamp":1794559932689,"version":"4.9.1"},"reference-count":94,"publisher":"American Medical Association (AMA)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2020,5,19]]},"abstract":"<jats:sec id=\"ab-jrv200003-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Approximately 125 million people worldwide have psoriasis. Patients with psoriasis experience substantial morbidity and increased rates of inflammatory arthritis, cardiometabolic diseases, and mental health disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv200003-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Plaque psoriasis is the most common variant of psoriasis. The most rapid advancements addressing plaque psoriasis have been in its pathogenesis, genetics, comorbidities, and biologic treatments. Plaque psoriasis is associated with a number of comorbidities including psoriatic arthritis, cardiometabolic diseases, and depression. For patients with mild psoriasis, topical agents remain the mainstay of treatment, and they include topical corticosteroids, vitamin D analogues, calcineurin inhibitors, and keratolytics. The American Academy of Dermatology-National Psoriasis Foundation guidelines recommend biologics as an option for first-line treatment of moderate to severe plaque psoriasis because of their efficacy in treating it and acceptable safety profiles. Specifically, inhibitors to tumor necrosis factor \u03b1 (TNF-\u03b1) include etanercept, adalimumab, certolizumab, and infliximab. Other biologics inhibit cytokines such as the p40 subunit of the cytokines IL-12 and IL-23 (ustekinumab), IL-17 (secukinumab, ixekizumab, bimekizumab, and brodalumab), and the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab, and mirikizumab). Biologics that inhibit TNF-\u03b1, p40IL-12\/23, and IL-17 are also approved for the treatment of psoriatic arthritis. Oral treatments include traditional agents such as methotrexate, acitretin, cyclosporine, and the advanced small molecule apremilast, which is a phosphodiesterase 4 inhibitor. The most commonly prescribed light therapy used to treat plaque psoriasis is narrowband UV-B phototherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv200003-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Psoriasis is an inflammatory skin disease that is associated with multiple comorbidities and substantially diminishes patients\u2019 quality of life. Topical therapies remain the cornerstone for treating mild psoriasis. Therapeutic advancements for moderate to severe plaque psoriasis include biologics that inhibit TNF-\u03b1, p40IL-12\/23, IL-17, and p19IL-23, as well as an oral phosphodiesterase 4 inhibitor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2020.4006","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T15:53:13Z","timestamp":1589903593000},"page":"1945","source":"Crossref","is-referenced-by-count":2350,"title":["Pathophysiology, Clinical Presentation, and Treatment of Psoriasis"],"prefix":"10.1001","volume":"323","author":[{"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[{"name":"Keck School of Medicine, Department of Dermatology, University of Southern California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Read","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, Department of Dermatology, University of Southern California Los Angeles"},{"name":"Department of Medicine, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"jrv200003r1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.2017.31.issue-2","article-title":"A systematic review of worldwide epidemiology of psoriasis.","volume":"31","author":"Michalek","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"jrv200003r3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States.","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"jrv200003r4","first-page":"187","article-title":"Prevalence of psoriasis in children and adolescents in the United States: a claims-based analysis.","volume":"17","author":"Paller","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"jrv200003r5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jaad.2008.12.032","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3, guidelines of care for the management and treatment of psoriasis with topical therapies.","volume":"60","author":"Menter","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"jrv200003r6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4, guidelines of care for the management and treatment of psoriasis with traditional systemic agents.","volume":"61","author":"Menter","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"jrv200003r7","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"jrv200003r8","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"jrv200003r9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jaad.2019.04.042","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.","volume":"81","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"jrv200003r10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Mechanisms of disease: psoriasis.","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv200003r11","first-page":"S2","article-title":"Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine.","volume":"33","author":"Alwan","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"jrv200003r12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence.","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"1","key":"jrv200003r13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdermsci.2011.03.002","article-title":"Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan.","volume":"63","author":"Tsai","year":"2011","journal-title":"J Dermatol Sci"},{"issue":"5","key":"jrv200003r14","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1086\/503821","article-title":"Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene.","volume":"78","author":"Nair","year":"2006","journal-title":"Am J Hum Genet"},{"key":"jrv200003r15","doi-asserted-by":"publisher","first-page":"15382","DOI":"10.1038\/ncomms15382","article-title":"Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants.","volume":"8","author":"Tsoi","year":"2017","journal-title":"Nat Commun"},{"issue":"3","key":"jrv200003r16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000041","article-title":"A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci.","volume":"4","author":"Liu","year":"2008","journal-title":"PLoS Genet"},{"issue":"4","key":"jrv200003r17","first-page":"214","article-title":"Inheritance of psoriasis: analysis of 2035 family histories [article in German].","volume":"33","author":"Andressen","year":"1982","journal-title":"Hautarzt"},{"issue":"9","key":"jrv200003r18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1001\/jamadermatol.2014.1019","article-title":"Psoriasis provoked or exacerbated by medications: identifying culprit drugs.","volume":"150","author":"Armstrong","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"10","key":"jrv200003r19","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","article-title":"Psoriasis severity and the prevalence of major medical comorbidity: a population-based study.","volume":"149","author":"Yeung","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"1","key":"jrv200003r20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2004.06.013","article-title":"Diagnosis and treatment of psoriatic arthritis.","volume":"52","author":"Mease","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"jrv200003r21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3899\/jrheum.140857","article-title":"Validation of the Toronto psoriatic arthritis screen version 2 (ToPAS 2).","volume":"42","author":"Tom","year":"2015","journal-title":"J Rheumatol"},{"issue":"4","key":"jrv200003r22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jaad.2007.04.001","article-title":"The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool.","volume":"57","author":"Husni","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"jrv200003r23","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/bjd.2013.168.issue-4","article-title":"Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study).","volume":"168","author":"Coates","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"jrv200003r24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3899\/jrheum.110845","article-title":"The ClASsification for Psoriatic ARthritis (CASPAR) criteria\u2014a retrospective feasibility, sensitivity, and specificity study.","volume":"39","author":"Tillett","year":"2012","journal-title":"J Rheumatol"},{"issue":"5","key":"jrv200003r25","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/bjd.2007.157.issue-5","article-title":"Multidisciplinary evaluation of patients with psoriasis presenting with musculoskeletal pain: a dermatology: rheumatology clinic experience.","volume":"157","author":"Mody","year":"2007","journal-title":"Br J Dermatol"},{"issue":"11","key":"jrv200003r26","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1001\/jamadermatol.2016.2907","article-title":"Comparison of coronary artery calcium scores between patients with psoriasis and type 2 diabetes.","volume":"152","author":"Mansouri","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"3","key":"jrv200003r27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1161\/CIRCULATIONAHA.116.026859","article-title":"Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study.","volume":"136","author":"Lerman","year":"2017","journal-title":"Circulation"},{"issue":"7","key":"jrv200003r28","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.amjcard.2011.11.025","article-title":"Coronary artery disease in patients with psoriasis referred for coronary angiography.","volume":"109","author":"Armstrong","year":"2012","journal-title":"Am J Cardiol"},{"issue":"9","key":"jrv200003r29","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1001\/jamacardio.2017.1213","article-title":"Association between skin and aortic vascular inflammation in patients with psoriasis: a case-cohort study using positron emission tomography\/computed tomography.","volume":"2","author":"Dey","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"6","key":"jrv200003r30","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.jaad.2015.02.1095","article-title":"Psoriasis and risk of diabetes-associated microvascular and macrovascular complications.","volume":"72","author":"Armstrong","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"jrv200003r31","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jaad.2012.08.015","article-title":"Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies.","volume":"68","author":"Armstrong","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"jrv200003r32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/2013.jamadermatol.406","article-title":"Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis.","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"14","key":"jrv200003r33","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis.","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"jrv200003r34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1365-2796.2010.02310.x","article-title":"Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.","volume":"270","author":"Ahlehoff","year":"2011","journal-title":"J Intern Med"},{"issue":"3","key":"jrv200003r35","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jaad.2010.01.050","article-title":"Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan.","volume":"64","author":"Lin","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"jrv200003r36","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1038\/jid.2009.112","article-title":"The risk of stroke in patients with psoriasis.","volume":"129","author":"Gelfand","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"16","key":"jrv200003r37","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1093\/eurheartj\/ehr285","article-title":"Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish nationwide cohort study.","volume":"33","author":"Ahlehoff","year":"2012","journal-title":"Eur Heart J"},{"issue":"3","key":"jrv200003r38","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","article-title":"Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK.","volume":"163","author":"Abuabara","year":"2010","journal-title":"Br J Dermatol"},{"issue":"5","key":"jrv200003r39","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/jid.2010.399","article-title":"Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk.","volume":"131","author":"Stern","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"2","key":"jrv200003r40","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies.","volume":"2","author":"Armstrong","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"jrv200003r41","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database.","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur Heart J"},{"issue":"3","key":"jrv200003r42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jaad.2017.05.019","article-title":"Psoriasis and suicidality: a systematic review and meta-analysis.","volume":"77","author":"Singh","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"jrv200003r43","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/jid.2013.508","article-title":"The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis.","volume":"134","author":"Dowlatshahi","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"4","key":"jrv200003r44","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries.","volume":"135","author":"Dalgard","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"10","key":"jrv200003r45","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1097\/MIB.0000000000001169","article-title":"Prevalence and phenotype of concurrent psoriasis and inflammatory bowel disease.","volume":"23","author":"Eppinga","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"jrv200003r46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1086\/345646","article-title":"A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting.","volume":"72","author":"Karason","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"1","key":"jrv200003r47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.2019.71.issue-1","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis.","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"jrv200003r48","first-page":"428","article-title":"Calcitriol 3 microg\/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies.","volume":"6","author":"Lebwohl","year":"2007","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"jrv200003r49","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/ijd.2015.54.issue-4","article-title":"The role of vitamin D in psoriasis: a review.","volume":"54","author":"Soleymani","year":"2015","journal-title":"Int J Dermatol"},{"issue":"2 Pt 1","key":"jrv200003r50","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0190-9622(97)70281-0","article-title":"Topical calcipotriol in childhood psoriasis.","volume":"36","author":"Oranje","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"jrv200003r51","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/j.1365-2133.1996.tb01501.x","article-title":"Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris.","volume":"135","author":"Darley","year":"1996","journal-title":"Br J Dermatol"},{"issue":"5","key":"jrv200003r52","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jaad.2004.06.010","article-title":"Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.","volume":"51","author":"Gribetz","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"jrv200003r53","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/bjd.2007.157.issue-5","article-title":"Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial.","volume":"157","author":"Liao","year":"2007","journal-title":"Br J Dermatol"},{"issue":"1","key":"jrv200003r54","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0190-9622(97)70216-0","article-title":"Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect.","volume":"37","author":"Weinstein","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"5 Pt 1","key":"jrv200003r55","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1067\/mjd.2000.107940","article-title":"Tazarotene plus UVB phototherapy in the treatment of psoriasis.","volume":"43","author":"Koo","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"jrv200003r56","first-page":"1468","article-title":"Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris\u2014a randomized phase III study (PSO-FAST).","volume":"14","author":"Leonardi","year":"2015","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"jrv200003r57","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5070\/D30W66C5GG","article-title":"A systematic review of adverse effects associated with topical treatments for psoriasis.","volume":"9","author":"Bruner","year":"2003","journal-title":"Dermatol Online J"},{"issue":"2","key":"jrv200003r58","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jaad.2018.03.040","article-title":"Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase 3 randomized controlled trials.","volume":"79","author":"Gold","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"jrv200003r59","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jaad.2018.09.002","article-title":"Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis.","volume":"80","author":"Lebwohl","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"9993","key":"jrv200003r60","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"jrv200003r61","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/jde.2016.43.issue-4","article-title":"Proactive treatment with calcipotriol reduces recurrence of plaque psoriasis.","volume":"43","author":"Ito","year":"2016","journal-title":"J Dermatol"},{"issue":"6","key":"jrv200003r62","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/bjd.2005.152.issue-6","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"issue":"3","key":"jrv200003r63","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis.","volume":"358","author":"Paller","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv200003r64","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial.","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"jrv200003r65","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"jrv200003r66","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaad.2018.04.012","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).","volume":"79","author":"Gottlieb","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"9494","key":"jrv200003r67","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"jrv200003r68","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).","volume":"165","author":"Barker","year":"2011","journal-title":"Br J Dermatol"},{"issue":"4","key":"jrv200003r69","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials.","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv200003r70","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study.","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"jrv200003r71","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","article-title":"Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial.","volume":"76","author":"Gottlieb","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"jrv200003r72","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/bjd.v181.5","article-title":"Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.","volume":"181","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"issue":"4","key":"jrv200003r73","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","article-title":"The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.","volume":"77","author":"Bagel","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"jrv200003r74","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.","volume":"79","author":"Mease","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"jrv200003r75","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2018.06.039","article-title":"Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study.","volume":"80","author":"Paul","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"14","key":"jrv200003r76","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis.","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"issue":"9625","key":"jrv200003r77","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"jrv200003r78","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.","volume":"73","author":"Landells","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"jrv200003r79","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv200003r80","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator\u2013controlled VOYAGE 1 trial.","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10201","key":"jrv200003r81","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"10091","key":"jrv200003r82","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"issue":"10148","key":"jrv200003r83","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"issue":"10198","key":"jrv200003r84","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"10068","key":"jrv200003r85","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S0140-6736(16)32127-4","article-title":"An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"389","author":"Warren","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"jrv200003r86","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"jrv200003r87","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1111\/jdv.2013.27.issue-3","article-title":"Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study.","volume":"27","author":"Dogra","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"jrv200003r88","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1056\/NEJM199101313240501","article-title":"Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial.","volume":"324","author":"Ellis","year":"1991","journal-title":"N Engl J Med"},{"key":"jrv200003r89","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis.","author":"Armstrong","journal-title":"JAMA Dermatol"},{"issue":"4","key":"jrv200003r90","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jaad.2011.04.004","article-title":"The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study.","volume":"66","author":"Stern","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"jrv200003r91","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jaad.2014.08.050","article-title":"OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.","volume":"72","author":"Kimball","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"jrv200003r92","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s13555-017-0198-x","article-title":"Long-term safety and effectiveness of adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT registry.","volume":"7","author":"Menter","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9","key":"jrv200003r93","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR).","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"11","key":"jrv200003r94","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis.","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"jrv200003r2","unstructured":"World Health Organization. Global Report on Psoriasis: World Health Organization, 2016. Accessed February 13, 2020. https:\/\/apps.who.int\/iris\/handle\/10665\/204417"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2766169\/jama_armstrong_2020_rv_200003_1715263002.46874.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T11:01:31Z","timestamp":1715252491000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2766169"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":94,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2020,5,19]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.4006","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1186\/s12979-026-00580-w","asserted-by":"object"}]},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,19]]}}}